Adam JacksonJanuary 5, 2024
The move marks a departure from the firm's previous reliance on philanthropic funding.
Tag: MDMA
Adam JacksonJanuary 5, 2024
John SchroyerDecember 12, 2023
The FDA has 60 days to decide if the application will be accepted for review.
Adam JacksonOctober 4, 2023
Research results indicated positive signals.
John SchroyerSeptember 14, 2023
MAPS is preparing to submit a formal new drug application to the FDA by end of year
Adam JacksonJuly 18, 2023
The company's also cutting costs and streamlining where it can to grab more margin.
Adam JacksonJune 27, 2023
Public comment on the draft proposal will be collected for the next 60 days.
StaffJune 23, 2023
This story was republished with permission from Crain’s New York. A significant player in the psychedelics industry has received a $5 million infusion from hedge-fund billionaire and New York Mets owner Steve Cohen and his wife, deepening the couple’s efforts to bring mind-altering therapies into the mainstream. The Steven & Alexandra Cohen Foundation is donating […]
Adam JacksonApril 3, 2023
The company's debts totaled C$136.5 million by the end of 2022.
John SchroyerMarch 29, 2023
Costs of the therapy are estimated at up to $15,000.
Debra BorchardtFebruary 8, 2023
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) is submitting a clinical trial application (CTA) for a Phase I combinatorial study that will document the safety of Optimi’s natural psilocybin standardized extract and proprietary 3,4-methylenedioxy-methamphetamine (MDMA) drug candidate in healthy therapist subjects. The single site, double-blind, five arm study will include 25 participants randomized into one of […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.